Artwork

Το περιεχόμενο παρέχεται από το Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.
Player FM - Εφαρμογή podcast
Πηγαίνετε εκτός σύνδεσης με την εφαρμογή Player FM !

Becoming All Of Our Selves with Dr. Paula O'Connor, Part I

23:46
 
Μοίρασέ το
 

Manage episode 287505617 series 2816013
Το περιεχόμενο παρέχεται από το Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

We are so excited for this next episode with our special guest, Dr. Paula O'Connor! We talk about finding your path in medicine and all of the many opportunities there are to follow your passions within the medical field. Dr. O'Connor gave us so many gems development of career and development of self.

About Dr. Paula O'Connor

Dr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.

Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).

Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.

Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.

Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.

--

New Episodes every Tuesday, available wherever you get your podcasts!

Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!

Sign Up for our newsletter here or at 3BlackDocs.com

A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients.

Learn more about Oncopeptides at https://www.oncopeptides.com/en

Join the Conversation! Follow us on social media!

3 Black Docs

facebook.com/3blackdocs
twitter.com/3blackdocs
instagram.com/3blackdocs
YouTube.com/3blackdocs

Dr. Karen Winkfield

facebook.com/drwinkfield
twitter.com/drwinkfield
instagram.com/drwinkfield

Dr. Zanetta Lamar

facebook.com/drzanetta
instagram.com/drzanetta

  continue reading

94 επεισόδια

Artwork
iconΜοίρασέ το
 
Manage episode 287505617 series 2816013
Το περιεχόμενο παρέχεται από το Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Winkz Productions, Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

We are so excited for this next episode with our special guest, Dr. Paula O'Connor! We talk about finding your path in medicine and all of the many opportunities there are to follow your passions within the medical field. Dr. O'Connor gave us so many gems development of career and development of self.

About Dr. Paula O'Connor

Dr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.

Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).

Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.

Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.

Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.

--

New Episodes every Tuesday, available wherever you get your podcasts!

Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!

Sign Up for our newsletter here or at 3BlackDocs.com

A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients.

Learn more about Oncopeptides at https://www.oncopeptides.com/en

Join the Conversation! Follow us on social media!

3 Black Docs

facebook.com/3blackdocs
twitter.com/3blackdocs
instagram.com/3blackdocs
YouTube.com/3blackdocs

Dr. Karen Winkfield

facebook.com/drwinkfield
twitter.com/drwinkfield
instagram.com/drwinkfield

Dr. Zanetta Lamar

facebook.com/drzanetta
instagram.com/drzanetta

  continue reading

94 επεισόδια

Όλα τα επεισόδια

×
 
Loading …

Καλώς ήλθατε στο Player FM!

Το FM Player σαρώνει τον ιστό για podcasts υψηλής ποιότητας για να απολαύσετε αυτή τη στιγμή. Είναι η καλύτερη εφαρμογή podcast και λειτουργεί σε Android, iPhone και στον ιστό. Εγγραφή για συγχρονισμό συνδρομών σε όλες τις συσκευές.

 

Οδηγός γρήγορης αναφοράς